Taiwan · Delayed Price · Currency is TWD Orient Pharma Statistics
Total Valuation
Orient Pharma has a market cap or net worth of TWD 6.04 billion. The enterprise value is 6.30 billion.
| Market Cap | 6.04B |
| Enterprise Value | 6.30B |
Important Dates
The next estimated earnings date is Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Orient Pharma has 223.04 million shares outstanding.
| Current Share Class | 223.04M |
| Shares Outstanding | 223.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | n/a |
| Float | 35.22M |
Valuation Ratios
The trailing PE ratio is 75.83.
| PE Ratio | 75.83 |
| Forward PE | n/a |
| PS Ratio | 4.79 |
| PB Ratio | 3.26 |
| P/TBV Ratio | 4.27 |
| P/FCF Ratio | 25.78 |
| P/OCF Ratio | 23.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.70, with an EV/FCF ratio of 26.89.
| EV / Earnings | 79.08 |
| EV / Sales | 4.99 |
| EV / EBITDA | 22.70 |
| EV / EBIT | 43.67 |
| EV / FCF | 26.89 |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.76 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 2.01 |
| Interest Coverage | 11.70 |
Financial Efficiency
Return on equity (ROE) is 4.39% and return on invested capital (ROIC) is 3.79%.
| Return on Equity (ROE) | 4.39% |
| Return on Assets (ROA) | 3.50% |
| Return on Invested Capital (ROIC) | 3.79% |
| Return on Capital Employed (ROCE) | 6.96% |
| Revenue Per Employee | 7.30M |
| Profits Per Employee | 460,740 |
| Employee Count | 173 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.99 |
Taxes
In the past 12 months, Orient Pharma has paid 44.97 million in taxes.
| Income Tax | 44.97M |
| Effective Tax Rate | 36.07% |
Stock Price Statistics
The stock price has decreased by -4.91% in the last 52 weeks. The beta is -0.01, so Orient Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | -4.91% |
| 50-Day Moving Average | 26.51 |
| 200-Day Moving Average | 32.83 |
| Relative Strength Index (RSI) | 55.34 |
| Average Volume (20 Days) | 342,999 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orient Pharma had revenue of TWD 1.26 billion and earned 79.71 million in profits. Earnings per share was 0.36.
| Revenue | 1.26B |
| Gross Profit | 664.60M |
| Operating Income | 144.34M |
| Pretax Income | 124.68M |
| Net Income | 79.71M |
| EBITDA | 258.11M |
| EBIT | 144.34M |
| Earnings Per Share (EPS) | 0.36 |
Balance Sheet
The company has 212.58 million in cash and 471.35 million in debt, giving a net cash position of -258.78 million or -1.16 per share.
| Cash & Cash Equivalents | 212.58M |
| Total Debt | 471.35M |
| Net Cash | -258.78M |
| Net Cash Per Share | -1.16 |
| Equity (Book Value) | 1.86B |
| Book Value Per Share | 8.33 |
| Working Capital | 361.43M |
Cash Flow
In the last 12 months, operating cash flow was 254.60 million and capital expenditures -20.16 million, giving a free cash flow of 234.44 million.
| Operating Cash Flow | 254.60M |
| Capital Expenditures | -20.16M |
| Free Cash Flow | 234.44M |
| FCF Per Share | 1.05 |
Margins
Gross margin is 52.65%, with operating and profit margins of 11.43% and 6.31%.
| Gross Margin | 52.65% |
| Operating Margin | 11.43% |
| Pretax Margin | 9.88% |
| Profit Margin | 6.31% |
| EBITDA Margin | 20.45% |
| EBIT Margin | 11.43% |
| FCF Margin | 18.57% |
Dividends & Yields
Orient Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 1.32% |
| FCF Yield | 3.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.
| Last Split Date | May 23, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.6500936135 |
Scores
Orient Pharma has an Altman Z-Score of 6.95 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.95 |
| Piotroski F-Score | 7 |